DeepMed Research

Nicotinamide

Generic Name: Nicotinamide

Brand Names: Alertonic, Fortaplex, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Nicomide, Pregvit, Tandem Plus

Drug Type: Small Molecule

Chemical Formula: C_₆H_₆N_₂O

CAS Number: 98-92-0

Unique Ingredient Identifier: 25X51I8RD4

Background: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.

Indication: 用于防治糙皮病等烟酸缺乏病，也用于防治心脏传导阻滞。

Associated Conditions: Gastrointestinal insufficiency, Hepatic Insufficiency, Macrocytic anemia, Secondary anemia, Vitamin Deficiency, Severe debilitation

Associated Therapies: Dietary and Nutritional Therapies, Nutritional supplementation, Dietary supplementation

Clinical Trials

The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients

Phase 2

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Nicotinamide Tablet
Drug: conventional synthetic antirheumatic drugs

First Posted Date: 2024-10-15

Last Posted Date: 2024-10-16

Lead Sponsor: Ain Shams University

Target Recruit Count: 70

Registration Number: NCT06640309

Locations: 🇪🇬
Ain Shams University Hospitals, Cairo, Egypt

Study of the Efficacy and Safety of Nicotinamide in Patients with Diabetes Mellitus Type 2 and Liver Fibrosis (NICOFIB)

Phase 2

Recruiting

Conditions: Fatty Liver
Obesity
Diabete Type 2
Hepatic Fibrosis
NAFLD
Nicotinamide

Interventions: Drug: Placebo
Drug: Nicotinamide

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 30

Registration Number: NCT06599918

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls

Phase 2

Recruiting

Conditions: Frailty
Fall
Frailty Syndrome
Falls

Interventions: Drug: Placebo
Drug: Nicotinamide

First Posted Date: 2024-06-20

Last Posted Date: 2024-06-20

Lead Sponsor: University of Chile

Target Recruit Count: 60

Registration Number: NCT06465602

Locations: 🇨🇱
Hospital Clínico Universidad de Chile, Santiago, Chile

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Phase 1

Recruiting

Conditions: Smooth Muscle Dysfunction Syndrome (SMDS)

Interventions: Drug: Nicotinamide riboside (NR)

First Posted Date: 2024-02-28

Last Posted Date: 2024-04-05

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 5

Registration Number: NCT06280482

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

Tolerance and Efficacy Nicotinamide (vitamin B3) in Dominant Optic Atrophy OPA1

Phase 2

Recruiting

Conditions: Nicotinamide Adverse Reaction

Interventions: Drug: Nicotinamide

First Posted Date: 2023-08-23

Last Posted Date: 2025-02-24

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 25

Registration Number: NCT06007391

Locations: 🇫🇷
Angers University Hospital, Angers, France

Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury

Phase 3

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Vitamin B3
Drug: Vitamin B12

First Posted Date: 2023-07-24

Last Posted Date: 2023-07-24

Lead Sponsor: KRL Hospital, Islamabad

Target Recruit Count: 300

Registration Number: NCT05958277

Locations: 🇵🇰
KRL Hospital, Islamabad, Pakistan

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

Phase 3

Recruiting

Conditions: Carcinoma, Squamous Cell
Keratinocyte Carcinoma
Carcinoma, Basal Cell
Non-melanoma Skin Cancer

Interventions: Drug: Nicotinamide
Drug: Placebo

First Posted Date: 2023-07-21

Last Posted Date: 2025-02-21

Lead Sponsor: Women's College Hospital

Target Recruit Count: 396

Registration Number: NCT05955924

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

and more 4 locations

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Early Phase 1

Not yet recruiting

Conditions: Skin Cancer
Kidney Transplant Recipients

Interventions: Drug: Vitamin A
Drug: Nicotinamide

First Posted Date: 2023-01-27

Last Posted Date: 2023-01-27

Lead Sponsor: Rhode Island Hospital

Target Recruit Count: 30

Registration Number: NCT05702398

Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant

Phase 3

Completed

Conditions: Delayed Graft Function

Interventions: Drug: Placebo treatment
Drug: Nicotinamide treatment

First Posted Date: 2022-08-24

Last Posted Date: 2024-07-10

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 204

Registration Number: NCT05513807

Locations: 🇫🇷
Department of Renal Transplantation - Hospital Pitié Salpétrière, Paris, France

Topical Nicotinamide in Treatment of DLE

Early Phase 1

Completed

Conditions: Discoid Lupus Erythematosus

Interventions: Drug: Nicotinamide Topical

First Posted Date: 2022-05-05

Last Posted Date: 2022-10-25

Lead Sponsor: Al-Azhar University

Target Recruit Count: 60

Registration Number: NCT05362188

Locations: 🇪🇬
AL-Azhar University Hospital, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy